Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.6452W HIGH $21.53
Volume
2.99 M
Value Traded
64.31 M
Short % Float
8.61%
Days to Cover
5.4
+0.28%Week
+0.7%1 Month
+76.48%3 Month
+188.22%6 Month
-13.88%5 Year
-13.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.22 B
EPS (TTM)
-1.04
P/E Ratio
-
Ent. Value
1.79 B
Total Shares
102.62 M
Float Shares
76.45 M
Insiders
26.57%
Institutions
68.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DAWN Catalyst Timeline
Dated clinical, regulatory and corporate events for Day One Biopharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How DAWN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-04-23 | Tovorafenib (DAY101) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: latest annual revenue in its 10-K, to Dec 2025; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| OJEMDA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emi-Le Small moleculeNCT05377996 | Triple Negative Breast Cancer | Phase 1 | RECRUITING | 360 | Dec 1, 2027 | ||||||
| DAY301 Small moleculeNCT06752681 | Advanced or Metastatic Solid Tumors | Phase 1 | RECRUITING | 300 | Dec 1, 2028 | ||||||
| upifitamab rilsodotin Monoclonal antibodyNCT03319628 | Platinum Resistant Ovarian Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 727 | Oct 31, 2024 | ||||||
| Tovorafenib Small moleculeMarketedNCT05566795 | Low-grade Glioma | Phase 3 | ACTIVE NOT_RECRUITING | 559 | Jun 1, 2031 | ||||||
| DAY101 Small moleculeMarketedNCT03429803 | Low-grade Glioma | Phase 1 | COMPLETED | 44 | Dec 31, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every DAWN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OJEMDA (tovorafenib) BreakthroughPriorityAccelerated+2 | pediatric low-grade glioma (pLGG) | Phase 2 | 2025-11-24 | patients off therapy: 77%; median time to next treatment: 3.5 years; overall response rate: 53% (40/76); median duration of response: 19.4 months (95% CI [13.8-27.2]); time to response: 5.4 months (range [1.6-17.5]); median progression free survival: 16.6 months (10.9-22.0)Read More | Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting Updated data expands clinically meaningful results available from Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bender JeremyDirector, Officer (CHIEF EXECUTIVE OFFICER) | Disposition | -204,643 | $0.00 | 04/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DAWN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.7 % (133.3 %) | 37.64 M | 1.76 M | 215.76% ( 1.20 M) |
DAWN Institutional Ownership Trends
DAWN Short Interest
Shares sold short, counted twice a month.
8.61%
Short % of Float
of tradable shares sold short
6.6M
Shares Sold Short
-9.1% vs prior count
5.4 High
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DAWN ranks across every disease it competes in
Competitive Position is a premium feature
See how DAWN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDAWN News
About Day One Biopharmaceuticals, Inc.
Headquarters1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE PLUS
Trade the next DAWN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime